Last reviewed · How we verify
Visine® for Contacts®
Visine® for Contacts® is a Ophthalmic decongestant Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently FDA-approved for Temporary relief of redness of the eye due to minor irritation in contact lens wearers.
Visine for Contacts is a decongestant eye drop that constricts blood vessels in the eye to reduce redness and irritation.
Visine for Contacts is a small molecule ophthalmic solution used to treat contact lens dry eye. It is a 1% azithromycin solution that has been studied in clinical trials for its effectiveness in managing contact lens-related dry eye.
At a glance
| Generic name | Visine® for Contacts® |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Ophthalmic decongestant |
| Target | Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
The active ingredient is tetrahydrozoline hydrochloride, an alpha-adrenergic agonist that causes vasoconstriction of the small blood vessels on the surface of the eye. This reduces blood flow to the conjunctiva, thereby decreasing redness and providing temporary relief from minor eye irritation. The formulation is specifically designed to be compatible with contact lens wear.
Approved indications
- Temporary relief of redness of the eye due to minor irritation in contact lens wearers
Common side effects
- Transient stinging or burning
- Rebound redness with prolonged use
- Mydriasis (pupil dilation)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Visine® for Contacts® CI brief — competitive landscape report
- Visine® for Contacts® updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Visine® for Contacts®
What is Visine® for Contacts®?
How does Visine® for Contacts® work?
What is Visine® for Contacts® used for?
Who makes Visine® for Contacts®?
What drug class is Visine® for Contacts® in?
What development phase is Visine® for Contacts® in?
What are the side effects of Visine® for Contacts®?
What does Visine® for Contacts® target?
Related
- Drug class: All Ophthalmic decongestant drugs
- Target: All drugs targeting Alpha-1 adrenergic receptor
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Temporary relief of redness of the eye due to minor irritation in contact lens wearers
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing